Discover eXciteOSA! ...the daytime alternative to CPAP
FDA‑cleared and Medicare‑reimbursable treatment for primary snoring and mild obstructive sleep apnea
Supports better sleep, energy, and overall wellbeing
Simple, comfortable, and non‑intrusive — no mask, no hose, no nighttime gear
Fits easily into your daytime routine
Guidance on how to get a prescription from your doctor
eXciteOSA is the first-ever FDA approved daytime treatment for adults with primary snoring and mild obstructive sleep apnea.
This patented device, developed by Signifier Medical Technologies, applies neuromuscular electrical stimulation in a novel approach to the tongue and upper airway muscles to address primary snoring and obstructive sleep apnea. While there are diverse medical devices available to mitigate sleep-disordered breathing, they focus primarily on temporarily alleviating symptoms during sleep. eXciteOSA’s daytime therapy addresses a key root cause, low muscle endurance, by stimulating the genioglossus and upper airway musculature to address collapsibility during sleep.
It’s a small, portable, intra-oral NMES device that uses electrodes above and below the tongue promoting a shift from fatigue-prone muscle fibers to fatigue-resistant muscle fibers. In clinical trials, adults that used the device for 20 mins a day for 6-weeks, saw a reduction in their AHI by an average of 52-57%.
Medicare + CMS Approved
96% Medicare reimbursement approval to-date, with over 200 claims so far.
A simple, intuitive, non‑intrusive and safe product that fits into daily life.
Innovative daytime therapy that treats the root cause of sleep apnea instead of masking symptoms.
Clinically validated, non‑invasive neuromuscular electrical stimulation therapy for mild obstructive sleep apnea and snoring.
Daytime treatment that fits into your routine—no mask, no hose, and no nighttime device to wear.
Average 52-57% reduction in AHI and ODI.
95% of patients experience objective snoring reduction, with a 48% decrease in time spent snoring.
81% adherence among real-world users, significantly higher than CPAP in mild cases.
Presented by Spectrum Sleep - Michael Shea, Director of Business Development